Videos

Karl Lewis, MD, medical oncologist, associate professor, University of Colorado, discusses sequencing immunotherapy and targeted therapy for patients with melanoma.

Giorgio V. Scagliotti, MD, PhD, discusses toxicities related to chemotherapy and surgery in patients with lung cancer.

Naomi B. Boekel, MSc, Netherlands Cancer Institute, Amsterdam, Netherlands, discusses DCIS patients' risk of dying from cardiovascular disease.

David P. Carbone, MD, PhD, describes variations in the accuracy and availability of genetic testing technologies for patients with lung cancer.

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses testing in patients with melanoma.

Elizabeth Mittendorf, MD, PhD, discusses the use of peptide vaccines for the treatment of breast cancer.

Don S. Dizon, MD, FACP, Medical Gynecologic Oncologist, Director of the Oncology Sexual Health Clinic, Massachusetts General Hospital, gives an overview of screening for ovarian cancer.

Vernon K. Sondak, MD, talks about personalized medicine when treating patients with melanoma.

Laurie Gaspar, MD, Professor and Chair Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses the risk of pneumonitis from radiation among patients with lung cancer.

Aditya Bardia, MD, MPH, discusses recent advancements in the field of breast cancer.

Grace Dy, MD, associate professor, Department of Medicine, Roswell Park Cancer Institute, discusses the anticipation of side effects from targeted therapies in clinical trials.

Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses different plasma testing approaches for patients with lung cancer.

Michael Birrer, MD, PhD, discusses the role of PARP inhibitors in ovarian cancer.

Jeffrey S. Weber, MD, PhD, discusses testing for genetic mutations in patients with melanoma.

Denise A. Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the role of Afinitor (everolimus) in breast cancer and the BOLERO trials.

Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in FDA’s Center for Drug Evaluation and Research, emphasizes the importance of adequate data supporting proposals to the FDA for breakthrough therapy designations.

Harvey I. Pass, MD, discusses some of the challenges of treating patients with mesothelioma

Deanna J. Attai, MD, surgeon, president, Center For Breast Care, Burbank, CA, discusses the overdiagnosis of breast cancer.

Karl Lewis, MD, discusses new and emerging treatments for metastatic melanoma.

Heather Wakelee, MD, discusses the results of the AVAPERL trial.

Jo Anne Zujewski, MD, head, breast cancer therapeutics, cancer therapy evaluation program, National Cancer Institute, discusses the FDA approval process for oncology drugs.

Anthony M. Magliocco, MD, discusses the difficulties of analyzing the genome of melanoma tumors.

Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, gives an overview of the background and results from a study that analyzed perioperative MRI and recurrence rates in women with DCIS.

Roy S. Herbst, MD, PhD, discusses targeting PD-1 and PD-L1 when treating patients with lung cancer.

Jeffrey A. Sosman, MD, discusses how immunotherapies work in patients with melanoma or renal cancer.

Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the use of erythropoiesis stimulating agents (ESAs) in patients with breast cancer.

Debu Tripathy, MD, discusses targeting HER2 in breast cancer.

Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

Jennifer Woyach, MD, discusses peripheral lymphocytosis in patients with chronic lymphocytic leukemia (CLL) following treatment with ibrutinib.

Komal L. Jhaveri, MD, Assistant Professor, Department of Medicine, NYU Langone Medical Center, discusses the background and results of a study looking at crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC).